Baseline characteristics
| Characteristic | Overall (n=461) | CoreValve (n=302) | Edwards (n=159) | p Value |
|---|---|---|---|---|
| Age (years) | 81.09±6.82 | 81.14±6.56 | 80.99±7.29 | 0.822 |
| Female | 258 (55.97) | 158 (52.32) | 100 (62.89) | 0.334 |
| Height (cm) | 165.81±8.96 | 166.36±8.71 | 164.79±9.35 | 0.073 |
| Weight (kg) | 72.70±15.25 | 72.85±14.98 | 72.44±15.77 | 0.784 |
| pAOD | 47 (10.2) | 30 (9.93) | 17 (10.69) | 0.871 |
| Hypertension | 356 (77.22) | 243 (80.46) | 113 (71.07) | 0.020 |
| Diabetes | 129 (27.98) | 89 (29.47) | 40 (25.16) | 0.383 |
| Dyslipidaemia | 189 (41) | 137 (45.36) | 52 (32.7) | 0.009 |
| Former smoker | 54 (11.71) | 42 (13.91) | 12 (7.55) | 0.047 |
| Previous MI | 45 (9.76) | 30 (9.93) | 15 (9.43) | 0.907 |
| Previous PCI | 224 (48.59) | 173 (57.28) | 51 (32.08) | <0.001 |
| Previous CABG | 51 (11.06) | 35 (11.59) | 16 (10.06) | 0.755 |
| Atrial fibrillation | 147 (31.89) | 98 (32.45) | 49 (30.82) | 0.753 |
| Pacemaker | 48 (10.41) | 30 (9.93) | 18 (11.32) | 0.634 |
| Previous BAV | 21 (4.56) | 18 (5.96) | 3 (1.89) | 0.058 |
| Previous stroke | 48 (10.41) | 31 (10.26) | 17 (10.69) | 0.874 |
| Creatinine max | 1.95±1.70 | 1.98±1.67 | 1.90±1.77 | 0.632 |
| COPD | 54 (11.71) | 38 (12.58) | 16 (10.06) | 0.451 |
| LVEF <40% | 58 (12.58) | 45 (14.9) | 13 (8.18) | 0.039 |
| Neoplasia | 99 (21.48) | 64 (21.19) | 35 (22.01) | 0.905 |
| Logistic euroSCORE | 16.27±14.18 | 22.76±11.65 | 18.46±9.63 | <0.001 |
| β Blocker | 289 (62.69) | 181 (59.93) | 108 (67.92) | 0.105 |
| Statin | 270 (58.57) | 188 (62.25) | 82 (51.57) | 0.028 |
| ACE inhibitors or ARB | 345 (74.84) | 236 (78.15) | 109 (68.55) | 0.031 |
| Aspirin | 389 (84.38) | 267 (88.4) | 122 (76.73) | 0.002 |
| Clopidogrel | 359 (77.87) | 266 (88.08) | 93 (58.49) | <0.001 |
Values are mean±SD or number (%). Units for creatinine: mg/dl.
ARB, angiotensin receptor blocker; BAV, balloon aortic valvuloplasty; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; pAOD, peripheral artery occlusive disease; PCI, percutaneous coronary intervention.